Natixis Advisors L.P. Has $110.04 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Natixis Advisors L.P. grew its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 61.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,147,607 shares of the biopharmaceutical company’s stock after acquiring an additional 816,561 shares during the period. Natixis Advisors L.P.’s holdings in Pfizer were worth $110,043,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Harbor Investment Advisory LLC lifted its holdings in Pfizer by 3.6% during the 4th quarter. Harbor Investment Advisory LLC now owns 23,977 shares of the biopharmaceutical company’s stock worth $1,229,000 after purchasing an additional 825 shares during the last quarter. Saxon Interests Inc. increased its stake in Pfizer by 12.9% during the 3rd quarter. Saxon Interests Inc. now owns 8,309 shares of the biopharmaceutical company’s stock worth $367,000 after acquiring an additional 951 shares during the period. Platte River Wealth Advisors LLC raised its holdings in Pfizer by 62.8% in the 3rd quarter. Platte River Wealth Advisors LLC now owns 12,717 shares of the biopharmaceutical company’s stock valued at $556,000 after acquiring an additional 4,905 shares in the last quarter. Accuvest Global Advisors lifted its position in shares of Pfizer by 16.6% during the 3rd quarter. Accuvest Global Advisors now owns 12,994 shares of the biopharmaceutical company’s stock valued at $569,000 after acquiring an additional 1,848 shares during the period. Finally, Secure Asset Management LLC raised its stake in Pfizer by 3.5% during the fourth quarter. Secure Asset Management LLC now owns 15,835 shares of the biopharmaceutical company’s stock worth $811,000 after acquiring an additional 537 shares in the last quarter. 67.62% of the stock is owned by institutional investors.

Get Pfizer alerts:

Insider Buying and Selling

In other Pfizer news, major shareholder Pfizer Inc bought 1,811,594 shares of the firm’s stock in a transaction on Friday, March 17th. The shares were acquired at an average cost of $2.76 per share, for a total transaction of $4,999,999.44. Following the purchase, the insider now directly owns 5,952,263 shares of the company’s stock, valued at $16,428,245.88. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.05% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on PFE shares. JPMorgan Chase & Co. set a $45.00 target price on shares of Pfizer in a research report on Monday, February 27th. Jefferies Financial Group began coverage on shares of Pfizer in a report on Monday, March 6th. They set a “hold” rating and a $43.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price target on shares of Pfizer in a research note on Wednesday, February 1st. Berenberg Bank set a $40.00 target price on Pfizer in a report on Tuesday, February 7th. Finally, Atlantic Securities decreased their target price on shares of Pfizer from $50.00 to $46.00 and set a “neutral” rating for the company in a research report on Wednesday, February 1st. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $49.93.

Pfizer Stock Performance

NYSE:PFE opened at $41.50 on Monday. Pfizer Inc. has a 1 year low of $39.23 and a 1 year high of $56.32. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.22 and a quick ratio of 1.00. The business has a fifty day simple moving average of $41.66 and a two-hundred day simple moving average of $45.47. The company has a market capitalization of $234.24 billion, a P/E ratio of 7.57, a P/E/G ratio of 1.40 and a beta of 0.64.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.11. The business had revenue of $24.30 billion for the quarter, compared to analysts’ expectations of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same period in the previous year, the business posted $1.08 EPS. On average, analysts expect that Pfizer Inc. will post 3.3 earnings per share for the current year.

About Pfizer

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

Featured Articles

• Get a free copy of the StockNews.com research report on Pfizer (PFE)
• MarketBeat Week in Review – 4/3 – 4/7
• Costco Sales Disappoint, Markets Are Missing This Upside Driver
• First Republic Bank Is A Speculative Play, Here’s Why
• The WD-40 Company Bottoms With Reversal In Sight 
• 3 Low-Cost Stock ETFs That Are Crushing It This Year

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.